# Novogene Challenges DoD Military-Company Designation

Novogene Co. and its U.S.-based subsidiary are challenging the Department of Defense’s designation of Novogene as a “Chinese military company” in the U.S. District Court for the District of Columbia. They argue that the designation lacks sufficient evidence and violates the Administrative Procedure Act and Fifth Amendment due process protections. The case could affect Novogene’s eligibility for U.S. government business, but the available reporting does not specify the applicable list restrictions or a court outcome.

- Federal procurement teams and contractors using Novogene or its subsidiary should assess potential exposure in their supply chains and evaluate the designation against the terms of relevant solicitations and contracts.
- The challenge puts the evidentiary and procedural basis for a DoD military-company designation under judicial review; its procurement effects remain uncertain until the case outcome and applicable restrictions are clear.
- Biotech suppliers and their customers should distinguish the existence of the designation from the unresolved litigation and avoid assuming that the case has established a specific government-business prohibition.

**Jurisdictions:** federal
**Industries:** Defense & Military
**Topics:** Regulatory Compliance
**Published:** November 04, 2026

### Government Entities
- U.S. Department of Defense (DoD)
- U.S. District Court for the District of Columbia

### Vendors
- Novogene Co. (Challenger to DoD designation)
- Novogene’s U.S.-based subsidiary (name not stated) (Co-challenger to DoD designation)